Immunic says first patient enrolled in investigator-sponsored post-COVID syndrome trial

Proactive - Interviews for investors

Immunic Inc chief medical officer Dr Andreas Muehler speaks to Proactive's Stephen Gunnion about the start of an investigator-sponsored Phase 2 clinical trial focused on treating Post COVID Syndrome (PCS) with its lead compound, vidofludimus calcium. This drug is currently in Phase 3 trials for multiple sclerosis and has shown potential as a broad-spectrum antiviral. Muehler explained that the trial, initiated by a group of German investigators, aims to investigate the role of viral reactivation in fatigue symptoms associated with PCS. The study builds on Immunic’s earlier work during the COVID-19 pandemic, which hinted at the drug's ability to reduce fatigue in hospitalized patients. Muehler highlighted the potential connection between Epstein-Barr virus reactivation and fatigue, a key area of interest that may also have implications for multiple sclerosis treatment. “We are hopeful that this trial will provide supportive data linking virus reactivation and fatigue,” said Muehler. Watch the video to learn more about the study, and why this trial could have a broader impact on Immunic’s ongoing research in multiple sclerosis. For more videos, don’t forget to like, subscribe to the Proactive YouTube channel, and hit the notification bell to stay updated. #ImmunicInc #PostCovidSyndrome #LongCovidTreatment #ClinicalTrials #VidofludimusCalcium #BroadSpectrumAntiviral #MultipleSclerosis #EpsteinBarrVirus #FatigueTreatment #COVID19Research #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews